Icodextrin
Explore a selection of our essential drug information below, or:
Identification
- Summary
Icodextrin is an iso-osmotic solution used for continuous peritoneal dialysis or automated peritoneal dialysis.
- Brand Names
- Extraneal
- Generic Name
- Icodextrin
- DrugBank Accession Number
- DB00702
- Background
Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Synonyms
- Icodextrin
- Icodextrina
- Icodextrine
- Icodextrinum
Pharmacology
- Indication
Used for continuous ambulatory peritoneal dialysis (CAPD) of diabetic patients or automated peritoneal dialysis (APD) for the management of end-stage renal disease.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport via peritoneal lymphatic pathways.
- Mechanism of action
Icodextrin is a starch-derived, water-soluble glucose polymer linked by alpha (1-4) and alpha (1-6) glycosidic bonds with an average molecular weight between 13,000 and 19,000 daltons. It functions as a colloid osmotic agent to achieve ultrafiltration during long (12-16 hour) peritoneal dialysis dwells. In other words it helps clean waste out of the body when the kidneys are not functioning properly. Icodectrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration through the dwell. This is due to the fact that the polymer is minimially absorbed across the peritoneal membrane. Icodextrin achieves superior fluid removal compared with glucose-based dialysates.
- Absorption
40% of instilled icodextrin was absorbed from the peritoneal solution during a 12-hour dwell.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Icodextrin is metabolized by alpha-amylase into oligosaccharides with a lower degree of polymerization), including maltose, maltotriose, maltotetraose, and higher molecular weight species.
Hover over products below to view reaction partners
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.No interactions found.
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Adept (Baxter) / Dextrin, Caloreen (Baxter) / Icodial
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Extraneal Icodextrin (7.5 g/100mL) + Calcium chloride dihydrate (25.7 mg/100mL) + Sodium lactate (448 mg/100mL) + Magnesium chloride hexahydrate (5.08 mg/100mL) + Sodium chloride (535 mg/100mL) Injection, solution Intraperitoneal Baxter Healthcare Corporation 2002-12-20 Not applicable US Extraneal Icodextrin (75 g / L) + Calcium chloride (257 mg / L) + Sodium lactate (4.48 g / L) + Magnesium chloride (51 mg / L) + Sodium chloride (5.35 g / L) Solution Intraperitoneal Vantive Ulc 2000-01-20 Not applicable Canada EXTRANEAL Icodextrin (7.5 g) + Calcium chloride dihydrate (0.0257 g) + Sodium lactate (0.45 g) + Magnesium chloride hexahydrate (0.0051 g) + Sodium chloride (0.54 g) Solution Intraperitoneal Baxter S.P.A. 2007-05-11 Not applicable Colombia EXTRANEAL PERITON DIYALIZ COZELTISI (2000 ML CIFTLI TORBA, MINI KAPAKLI) Icodextrin (75 g/L) + Calcium chloride (0.257 g/L) + Sodium lactate (4.5 g/L) + Magnesium chloride hexahydrate (0.051 g/L) + Sodium chloride (5.4 g/L) Solution Intraperitoneal BAXTER TURKEY RENAL HİZMETLER A.Ş. 2016-08-04 Not applicable Turkey EXTRANEAL PERITON DIYALIZ ÇÖZELTİSİ, ÇIFTLI TORBA MINI KAPAKLI 2500 ML Icodextrin (75 g/L) + Calcium chloride (0.257 g/L) + Sodium lactate (4.5 g/L) + Magnesium chloride hexahydrate (0.051 g/L) + Sodium chloride (5.4 g/L) Solution Intraperitoneal BAXTER TURKEY RENAL HİZMETLER A.Ş. 2016-08-04 Not applicable Turkey
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 2NX48Z0A9G
- CAS number
- 337376-15-5
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Frampton JE, Plosker GL: Icodextrin: a review of its use in peritoneal dialysis. Drugs. 2003;63(19):2079-105. [Article]
- External Links
- PubChem Substance
- 46508585
- 140480
- ChEMBL
- CHEMBL1201472
- PharmGKB
- PA164743096
- RxList
- RxList Drug Page
- Wikipedia
- Icodextrin
- FDA label
- Download (243 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available End Stage Renal Disease (ESRD) 1 somestatus stop reason just information to hide Not Available Completed Treatment Chronic Kidney Disease (CKD) / Refractory Heart Failure 1 somestatus stop reason just information to hide Not Available Completed Treatment End Stage Renal Disease (ESRD) 1 somestatus stop reason just information to hide Not Available Not Yet Recruiting Treatment Peritoneal dialysis therapy 1 somestatus stop reason just information to hide Not Available Recruiting Not Available Renal Failure, Chronic Renal Failure 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Baxter healthcare corp
- Packagers
- Baxter International Inc.
- Dosage Forms
Form Route Strength Injection, solution Intraperitoneal Solution Intraperitoneal Solution Parenteral - Prices
Unit description Cost Unit Extraneal icodextrin dial soln 0.05USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US4761237 No 1988-08-02 2009-08-09 US US6077836 No 2000-06-20 2017-06-20 US US6248726 No 2001-06-19 2018-06-19 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 80 mg/mL Not Available - Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Not Available
- Specific Function
- alpha-amylase activity
- Gene Name
- AMY2A
- Uniprot ID
- P04746
- Uniprot Name
- Pancreatic alpha-amylase
- Molecular Weight
- 57706.51 Da
References
- Flore KM, Delanghe JR: Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int. 2009 Jul-Aug;29(4):377-83. [Article]
- Garcia-Lopez E, Lindholm B: Icodextrin metabolites in peritoneal dialysis. Perit Dial Int. 2009 Jul-Aug;29(4):370-6. [Article]
Drug created at June 13, 2005 13:24 / Updated at October 03, 2024 07:11